Delcath Systems (NASDAQ:DCTH) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• Delcath Systems has been downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, indicating a shift in analyst sentiment regarding the stock's performance.
• Despite the downgrade, other analysts have maintained a positive outlook, with one reissuing an "overweight" rating and another raising their target price from $29.00 to $31.00, with a consensus target price of $24.50.
• Delcath Systems reported an EPS of $0.07 for the last quarter, exceeding expectations, and had revenue of $24.16 million, surpassing analyst estimates.

Delcath Systems (NASDAQ:DCTH - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Sunday.

A number of other equities analysts have also issued reports on DCTH. Stephens reissued an "overweight" rating and issued a $25.00 price objective on shares of Delcath Systems in a report on Monday, June 23rd. HC Wainwright upped their target price on Delcath Systems from $29.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Delcath Systems currently has an average rating of "Moderate Buy" and a consensus target price of $24.50.

Delcath Systems Trading Down 1.8%

NASDAQ:DCTH opened at $10.01 on Friday. The firm has a market capitalization of $350.15 million, a PE ratio of 200.20 and a beta of 0.82. The stock has a 50 day moving average of $12.96 and a 200-day moving average of $13.60. Delcath Systems has a 52 week low of $7.17 and a 52 week high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.02 by $0.05. The company had revenue of $24.16 million during the quarter, compared to analyst estimates of $22.84 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. As a group, analysts predict that Delcath Systems will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new stake in Delcath Systems in the second quarter worth approximately $197,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at $97,000. Geode Capital Management LLC lifted its position in shares of Delcath Systems by 128.1% during the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company's stock valued at $9,565,000 after acquiring an additional 394,902 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at $162,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at $1,338,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.